Pharmaceutical company Sandoz recalled 14 lots of Ranitidine capsules for exceeding the Food and Drug Administration’s limits of a carcinogen.
The substance, NDMA (N-Nitrosodimethylamine), has also been behind the recall of many brands of the heart and blood pressure medications we have been telling you about in recent months.
Ranitidine, according to the recall notice treats “duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable.”
The lots included in this recall are the following:
- Ranitidine 150 mg capsules in 60 and 500-count bottles with lot Nos. HD1862HP9438, HP9439, HP9440, HP9441, HC9266, HD1865, JK7994, JK8659
- 300 mg capsules in 30-count bottles with lot Nos. HD8625, HD9275, HU2207, HX6676 and HX6677
If you take Ranitidine, consult with your doctor about an alternate course of treatment before stopping treatment as the risk to your health may be greater than expected.
Consumers with questions should call Sandoz at 800-525-8747.
Do you have additional information about this recall? Is there another recall you want us to cover? Tell us in the comments below. You can also contact us for more information! Feel free to shoot us an email to Outreach@ConsiderTheConsumer.com. You can also find us on Twitter, Facebook, Instagram, LinkedIn, or even connect with us directly on our website!
About the Author: Aisha K. Staggers is a writer, lecturer, political analyst and literary agent. She appears weekly for “Staggers’ State of Things” on the Dr. Vibe Show. Her work has been published by Paper Magazine, AfroPunk, The Spool, GREY Journal, MTV News, HuffPost, Blavity, Atlanta Blackstar, For Harriet, New York Review of Books and a host of other first-run publications and syndicated outlets. Find her on Twitter @AishaStaggers. For more of her work, check out her page here!